Efficacy of Topical Hydrocortisone in Combination with Topical Ciclosporin A for the Treatment of Dry Eye Disease in Patients with Sjögren Syndrome
Table 3
Study parameters at baseline and after 2 weeks and 6 months of treatment, separately for the two treatment regimens.
Baseline
2 weeks
6 months
OSDI
56.0 ± 18.2
42.1 ± 22.0
0.002
28.2 ± 15.5
<0.001
Ciclosporin A+hydrocortisone (CsA+Hc)
Visual Analogue Scale
39.0 ± 20.6
26.3 ± 19.4
<0.001
19.1 ± 17.7
<0.001
Tear BUT (sec)
2.8 ± 1.3
4.2 ± 1.3
0.008
5.4 ± 1.3
0.003
Fluorescein Oxford staining grade
3.3 ± 0.5
2.8 ± 0.7
0.025
1.6 ± 0.7
0.001
Lissamine Oxford staining grade
3.0 ± 0.9
2.7 ± 0.7
0.046
1.7 ± 0.8
0.002
Schirmer test (mm/5 min)
3.6 ± 1.8
4.6 ± 1.3
0.086
5.6 ± 1.9
0.049
MG dropout rate (%)
31.9 ± 12.7
—
—
30.6 ± 12.5
0.094
Corneal MTF
0.38 ± 0.11
—
—
0.50 ± 0.22
0.037
Corneal Strehl ratio
0.18 ± 0.13
—
—
0.30 ± 0.28
0.042
Intraocular pressure
14.0 ± 2.0
14.6 ± 2.0
0.289
14.4 ± 3.1
0.952
Ciclosporin A (CsA)
Visual Analogue Scale
35.9 ± 20.4
24.6 ± 19.9
0.002
20.9 ± 18.7
0.001
Tear BUT (sec)
3.4 ± 1.6
3.6 ± 1.6
0.493
5.0 ± 0.9
0.007
Fluorescein Oxford staining grade
3.1 ± 0.3
2.9 ± 0.7
0.317
1.8 ± 0.9
0.004
Lissamine Oxford staining grade
3.0 ± 0.9
2.6 ± 0.7
0.025
1.8 ± 0.9
0.002
Schirmer test (mm/5 min)
3.3 ± 1.4
4.1 ± 1.3
0.057
5.6 ± 2.0
0.050
MG dropout rate (%)
33.2 ± 12.1
—
—
31.8 ± 12.7
0.070
Corneal MTF
0.38 ± 0.15
—
—
0.40 ± 0.16
0.923
Corneal Strehl ratio
0.22 ± 0.21
—
—
0.23 ± 0.21
0.945
Intraocular pressure (mmHg)
14.2 ± 2.7
14.5 ± 2.0
0.757
14.4 ± 2.8
0.836
Data are presented as mean ± SD; : difference between baseline and values at 2 weeks and 6 months using t test for paired samples and Wilcoxon signed-rank test. Significant values are indicated in bold.